瑞格列奈治疗肾移植后糖尿病的疗效和安全性

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (534 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the efficacy and safety of repaglinide therapy in patients with post-transplantation diabetes mellitus(PTDM). Methods To all the patients diagnosed as having PTDM,recrnited in this hospital from January 1,2009 to June 30, 2010 repaglinide was administered for 6 months. Glucose level, hepatic and renal function indicators and FK-506 concentration were examined at baseline, 1 month, 3 months and 6 months of repaglinide therapy. Results 32 patients were included. Except 10 patrents who required insulin glargine therapy due to their poor blood glucose control, the remaining 22 cases received satisfactory glycemic control with repaglinide alone. The levels of FBG, PBG at 1 month, 3 months or 6 months of treatment were significantly lower than those at baseline respectively (P<0.05). The level of Hb1AC at 6 months (6.20%±0.3%) was significantly lower than that at baseline(7.50%±0.63%;P＜0.05). Indicators of hepatic and renal functions and serum FK-506 concentration showed no significant change before and after repaglinide therapy. In the course of treatment hypoglycemia occurred 6 times, in which the lowest blood glucose level was 3.7 mmol/L, no severe hypoglycemia oleveloped. Conclusions Repaglinide can be a safe and effective therapy in patients with PTDM.

Key words： posttransplantation diabetes mellitus repaglinide efficacy safety

Received: 15 October 2015

ZTFLH:

R581

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAN Fuqin
	XU Chun
	CHEN Haimei
	and NIU Yujian

Cite this article:

YAN Fuqin,XU Chun,CHEN Haimei等. A clinical study on repaglinide therapy of diabetes mellitus after renal transplantation[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(5): 449-451.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2016/V27/I5/449

[1]	Jelmesaeth J, Jessen T, Hartmann A. Diagnosing of PTDM[J]. Transplantation, 2003, 75(10):1761.
[2]	Eckhard M, Schindler R A, Renner F C, et al. New-onset diabetes mellitus after renal transplantation[J]. Transplant Proc, 2009, 41(6): 2544-2545.
[3]	Gomes M B, Cobas R A. Post-transplant diabetes mellitus[J]. Diabetol Metab Syndr, 2009, 1(1): 14.
[4]	Gnatta D, Keitel E, Heineck I, et al. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study[J]. Transplant Proc, 2010, 42(2): 475-478.
[5]	Pérez-Flores I, Sánchez-Fructuoso A, Calvo N, et al. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus[J]. Transplant Proc, 2010, 42(8): 2902-2904.
[6]	Davidson J A, Wilkinson A. New-onset diabetes after transplantation 2003 international consensus guidelines[J]. Diabetes Care, 2004,27(3):805-812.
[7]	Turk T, Pietruck F, Dolffa S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation[J]. Am J Transplant, 2006, 6(4): 842-846.
[8]	吴谊青,王少艳,毕会.瑞格列奈及罗格列酮对肾移植后糖尿病患者的疗效[J]. 天津医药, 2010, 38(4): 276-278.
[9]	Johansen O E, Birkeland K I. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review [J]. Am J Cardiovasc Drugs, 2007,7(5):319-335.